The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

Background: This study was designed to evaluate the effect of melatonin on nonalcoholic fatty liver disease (NAFLD) in compared to placebo. Materials and Methods: A total of 100 patients with histopathological diagnosis NAFLD in two groups of case and control received oral melatonin or placebo thric...

Full description

Bibliographic Details
Main Authors: Hassan Pakravan, Mehdi Ahmadian, Ali Fani, Davood Aghaee, Sareh Brumanad, Bahram Pakzad
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:Advanced Biomedical Research
Subjects:
Online Access:http://www.advbiores.net/article.asp?issn=2277-9175;year=2017;volume=6;issue=1;spage=40;epage=40;aulast=Pakravan
_version_ 1818062527693586432
author Hassan Pakravan
Mehdi Ahmadian
Ali Fani
Davood Aghaee
Sareh Brumanad
Bahram Pakzad
author_facet Hassan Pakravan
Mehdi Ahmadian
Ali Fani
Davood Aghaee
Sareh Brumanad
Bahram Pakzad
author_sort Hassan Pakravan
collection DOAJ
description Background: This study was designed to evaluate the effect of melatonin on nonalcoholic fatty liver disease (NAFLD) in compared to placebo. Materials and Methods: A total of 100 patients with histopathological diagnosis NAFLD in two groups of case and control received oral melatonin or placebo thrice daily for 3 months. Collected data were weight, waist, systolic blood pressure (SBP), diastolic blood pressure (DBP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), high sensitive C-reactive protein (hsCRP), fatty liver grade, and side effects which were measured at baseline and after treatment period using standard clinical chemistry techniques. Results: Before treatment the mean of weight, waist, SBP, DBP, ALT, AST, and hsCRP between cases and controls were similar (P > 0.5). After treatment, only the differences in the mean of hsCRP in cases was significantly lower than controls (P = 0.003). In case group, all variables after treatment were significantly decreased compare to baseline (P > 0.5) and only AST after treatment was similar to before treatment (P > 0.5). The mean of a decrease in the level of weight, waist, SBP, and ALT were not statistically significant between groups (P > 0.5). In the case group in compare to control group the level of DBP, AST, and hsCRP significantly more decreased. After treatment fatty, liver grade was statistically improved in more cases than controls (P = 0.001). Side effects were similar between the two groups. Conclusion: Melatonin significantly decreases liver enzymes, so the use of melatonin in patients with NAFLD can be effective.
first_indexed 2024-12-10T14:05:38Z
format Article
id doaj.art-9ca811df91d94f0c8f3977d7f2f265be
institution Directory Open Access Journal
issn 2277-9175
language English
last_indexed 2024-12-10T14:05:38Z
publishDate 2017-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Advanced Biomedical Research
spelling doaj.art-9ca811df91d94f0c8f3977d7f2f265be2022-12-22T01:45:40ZengWolters Kluwer Medknow PublicationsAdvanced Biomedical Research2277-91752017-01-0161404010.4103/2277-9175.204593The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled TrialHassan PakravanMehdi AhmadianAli FaniDavood AghaeeSareh BrumanadBahram PakzadBackground: This study was designed to evaluate the effect of melatonin on nonalcoholic fatty liver disease (NAFLD) in compared to placebo. Materials and Methods: A total of 100 patients with histopathological diagnosis NAFLD in two groups of case and control received oral melatonin or placebo thrice daily for 3 months. Collected data were weight, waist, systolic blood pressure (SBP), diastolic blood pressure (DBP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), high sensitive C-reactive protein (hsCRP), fatty liver grade, and side effects which were measured at baseline and after treatment period using standard clinical chemistry techniques. Results: Before treatment the mean of weight, waist, SBP, DBP, ALT, AST, and hsCRP between cases and controls were similar (P > 0.5). After treatment, only the differences in the mean of hsCRP in cases was significantly lower than controls (P = 0.003). In case group, all variables after treatment were significantly decreased compare to baseline (P > 0.5) and only AST after treatment was similar to before treatment (P > 0.5). The mean of a decrease in the level of weight, waist, SBP, and ALT were not statistically significant between groups (P > 0.5). In the case group in compare to control group the level of DBP, AST, and hsCRP significantly more decreased. After treatment fatty, liver grade was statistically improved in more cases than controls (P = 0.001). Side effects were similar between the two groups. Conclusion: Melatonin significantly decreases liver enzymes, so the use of melatonin in patients with NAFLD can be effective.http://www.advbiores.net/article.asp?issn=2277-9175;year=2017;volume=6;issue=1;spage=40;epage=40;aulast=PakravanLiver diseasemelatoninnonalcoholic fatty liver disease
spellingShingle Hassan Pakravan
Mehdi Ahmadian
Ali Fani
Davood Aghaee
Sareh Brumanad
Bahram Pakzad
The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
Advanced Biomedical Research
Liver disease
melatonin
nonalcoholic fatty liver disease
title The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
title_full The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
title_fullStr The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
title_full_unstemmed The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
title_short The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
title_sort effects of melatonin in patients with nonalcoholic fatty liver disease a randomized controlled trial
topic Liver disease
melatonin
nonalcoholic fatty liver disease
url http://www.advbiores.net/article.asp?issn=2277-9175;year=2017;volume=6;issue=1;spage=40;epage=40;aulast=Pakravan
work_keys_str_mv AT hassanpakravan theeffectsofmelatonininpatientswithnonalcoholicfattyliverdiseasearandomizedcontrolledtrial
AT mehdiahmadian theeffectsofmelatonininpatientswithnonalcoholicfattyliverdiseasearandomizedcontrolledtrial
AT alifani theeffectsofmelatonininpatientswithnonalcoholicfattyliverdiseasearandomizedcontrolledtrial
AT davoodaghaee theeffectsofmelatonininpatientswithnonalcoholicfattyliverdiseasearandomizedcontrolledtrial
AT sarehbrumanad theeffectsofmelatonininpatientswithnonalcoholicfattyliverdiseasearandomizedcontrolledtrial
AT bahrampakzad theeffectsofmelatonininpatientswithnonalcoholicfattyliverdiseasearandomizedcontrolledtrial
AT hassanpakravan effectsofmelatonininpatientswithnonalcoholicfattyliverdiseasearandomizedcontrolledtrial
AT mehdiahmadian effectsofmelatonininpatientswithnonalcoholicfattyliverdiseasearandomizedcontrolledtrial
AT alifani effectsofmelatonininpatientswithnonalcoholicfattyliverdiseasearandomizedcontrolledtrial
AT davoodaghaee effectsofmelatonininpatientswithnonalcoholicfattyliverdiseasearandomizedcontrolledtrial
AT sarehbrumanad effectsofmelatonininpatientswithnonalcoholicfattyliverdiseasearandomizedcontrolledtrial
AT bahrampakzad effectsofmelatonininpatientswithnonalcoholicfattyliverdiseasearandomizedcontrolledtrial